Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?

GKOS shares surge 36.8% in six months, fueled by strong sales, iDose TR and Epioxa expansion, higher guidance and promising clinical developments.

Zacks Investment Research • Oct 14, 2026

Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy

Ophthalmic pharmaceutical and medical technology firm Glaukos Corporation (NYSE:GKOS) reported successful topline outcomes from its latest Phase 4 clinical study.

Benzinga • Oct 9, 2026

Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal

GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rights, even as shares decline 6.3% following the news.

Zacks Investment Research • Oct 9, 2026

Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced positive topline results from the Phase 4 prospective, randomized, controlled clinical trial (GLK-101-04) evaluating iDose® TR administered in conjunction with cataract surgery compared to cataract surgery alone in patients with open-angle glaucoma (OA.

Business Wire • Oct 9, 2026

Glaukos: The Second J-Code Rewrites The Risk Math

Glaukos is transitioning from a single-product reimbursement story to a diversified ophthalmic pharmaceutical platform with two J-coded drugs and strong operating leverage. Q2 net sales grew 50% YoY to $185.6M, driven by iDose TR and the Epioxa launch, with non-GAAP gross margin reaching 85% and breakeven P&L. Management raised 2026 net sales guidance to $680–700M, with iDose TR sales expected at $275–280M and corneal health growth of 20%+.

Seeking Alpha • Oct 10, 2026

Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal

Glaukos Corporation (NYSE:GKOS) reported three-year trial results for its non-invasive keratoconus treatment while simultaneously securing an exclusive licensing deal to broaden its pipeline of retinal disease therapies.

Benzinga • Oct 8, 2026

Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced an exclusive license agreement with RevOpsis Therapeutics, Inc. to develop and commercialize RO-104, a novel tri-specific biologic for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macula edema (DME), diabetic retinopat.

Business Wire • Oct 8, 2026

Glaukos says late-stage eye disease treatment shows lasting benefits after single dose

Glaukos said on Wednesday patients treated with its late-stage eye disease therapy maintained improvements ​in vision and corneal shape three years ‌after a single treatment for keratoconus, a disease that can progressively distort vision.

Reuters • Oct 7, 2026

Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release third quarter 2026 financial results after the market close on Wednesday, October 28, 2026. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on October 28, 2026. A link.

Business Wire • Oct 7, 2026

Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today positive topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating the durability, visual outcomes, and safety of Epioxa®, the company's groundbreaking epi-on corneal cross-linking therapy for the treatment of keratoconus, a sigh.

Business Wire • Oct 7, 2026